Ensign Peak Advisors
LYRA

Ensign Peak Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Ensign Peak Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,826
Closed -$3.68M – 1731
2024
Q1 		$3.68M Buy
11,826
+5,795
+96% +$1.54M 0.01% 723
2023
Q4 		$1.58M Hold
6,031
– – ﹤0.01% 1040
2023
Q3 		$1.18M Sell
6,031
-14
-0.2% -$2.5K ﹤0.01% 1067
2023
Q2 		$1.24M Hold
6,045
– – ﹤0.01% 1091
2023
Q1 		$626K Hold
6,045
– – ﹤0.01% 1565
2022
Q4 		$949K Buy
6,045
+4,781
+378% +$946K ﹤0.01% 1197
2022
Q3 		$317K Buy
1,264
+139
+12% +$41.1K ﹤0.01% 1680
2022
Q2 		$318K Buy
1,125
+342
+44% +$93.1K ﹤0.01% 1657
2022
Q1 		$157K Hold
783
– – ﹤0.01% 1942
2021
Q4 		$171K Hold
783
– – ﹤0.01% 1957
2021
Q3 		$358K Hold
783
– – ﹤0.01% 1686
2021
Q2 		$314K Hold
783
– – ﹤0.01% 1672
2021
Q1 		$454K Hold
783
– – ﹤0.01% 1610
2020
Q4 		$447K Hold
783
– – ﹤0.01% 1622
2020
Q3 		$438K Buy
783
+483
+161% +$300K ﹤0.01% 1564
2020
Q2 		$170K Buy
+300
New +$219K ﹤0.01% 1596

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's LYRA Position: Q2 2024 in Review

Ensign Peak Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2024, closing a stake of 11,826 shares — an estimated $3.68M sold.

Ensign Peak Advisors first reported a position in LYRA in Q2 2020 and held it in 16 quarters. The position peaked at $3.68M in Q1 2024. 51 funds tracked by Wall St. Rank hold LYRA as of Q2 2024.

  • Ensign Peak Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 11,826 LYRA THERAPEUTICS INC shares in Q2 2024, an estimated $3.68M.
  • Ensign Peak Advisors first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 16 quarters.
  • Ensign Peak Advisors's LYRA THERAPEUTICS INC position peaked at $3.68M in Q1 2024.
  • 51 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.